Piperacillin
(PIPC) is a broad-spectrum penicillin1} and has been one of the most useful /Mactam antibiotics over the past 10 years. An active metabolite of PIPC previously reported is a ringopening product at 2,3-dioxopiperazine moiety (T-1220A) in rat2), but there is no report on active metabolites in human.
In the course of clinical study for the coadministration ofPIPC with a /Mactamase inhibitor, tazobactam3), an active metabolite ofPIPC (1) which is distinct from T-1220A was found in human plasma and urine. The metabolite 1 was also found in the same manneron the administration of PIPCalone, suggesting that the metabolism of PIPC was not affected by the co-administration of tazobactam. The pharmacokinetic properties of 1 in human will be reported elsewhere. Herein we wish to describe the isolation, structural determination and antimicrobial activity of 1. (A) Authentic PIPC, (B) YP-14 (2.5 g) infusion group, (C) PIPC (2.0 g) infusion group.
Plasma were obtained at 2. hours, and urine were collected during 6~8 hours period after start of infusion. The antimicrobial activity of 1 together with PIPC determined by 2-fold serial agar dilution method are shown in Table 2 . 1 was as potent as PIPC against Gram-positive bacteria, but it is several times less active than PIPC against Gram-negative becteria except Morganella morganii and Proteus vulgaris. 
